Literature DB >> 3042767

Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases.

K A Joiner1, W D daSilva, M T Rimoldi, C H Hammer, A Sher, T L Kipnis.   

Abstract

Infective- and vertebrate-stage trypomastigotes of Trypanosoma cruzi resist serum killing by the alternative complement pathway, whereas noninfective vector-stage epimastigotes, from which trypomastigotes derive, are serum-sensitive. This form of developmental preadaption is commonly observed in protozoan parasites, but its mechanisms are poorly understood. We have demonstrated previously that trypomastigotes spontaneously shed molecules which interfere with formation and accelerate the intrinsic decay of complement C3 convertases, a finding which may explain the evasion of complement lysis by trypomastigotes. We now describe the partial purification and characterization of the T. cruzi C3 convertase inhibitor from the supernatant of culture metacyclic and tissue culture trypomastigotes. Decay-accelerating activity for both classical and alternative pathway C3 convertases copurifies on anion-exchange fast protein liquid chromatography and chromatofocusing with 35S-labeled molecules of 87-93 kDa, pI 5.6-5.8. The labeled components are destroyed by papain and retained on concanavalin A-Sepharose, procedures which remove functional decay-accelerating activity from the supernatant. The 87-93-kDa components are immunoprecipitated by sera from patients chronically infected with T. cruzi, but not by antisera to any known regulatory proteins of the human complement cascade. Lytic activity for tissue culture trypomastigotes in chagasic sera is associated with antibody reactivity against the 87-93-kDa 35S-labeled components and with inhibition of decay-accelerating activity. The T. cruzi factor is the first developmentally regulated microbial complement inhibitor to be biochemically characterized.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042767

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  The major surface glycoprotein of Trypanosoma cruzi amastigotes are ligands of the human serum mannose-binding protein.

Authors:  S J Kahn; M Wleklinski; R A Ezekowitz; D Coder; A Aruffo; A Farr
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.

Authors:  M T Rimoldi; A J Tenner; D A Bobak; K A Joiner
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 3.  Complement evasion by parasites: search for "Achilles' heel".

Authors:  Z Fishelson
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

4.  Modulation of sensitivity of blood forms of Trypanosoma cruzi to antibody-mediated, complement-dependent lysis.

Authors:  F Kierszenbaum; M A Ramirez
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

5.  Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor.

Authors:  S Kahn; M Wleklinski; A Aruffo; A Farr; D Coder; M Kahn
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

6.  A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF.

Authors:  D V Tambourgi; T L Kipnis; W D da Silva; K A Joiner; A Sher; S Heath; B F Hall; G B Ogden
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

7.  Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies.

Authors:  K A Norris; G Harth; M So
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

8.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

Review 9.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

10.  Further characterization of protective Trypanosoma cruzi-specific CD4+ T-cell clones: T helper type 1-like phenotype and reactivity with shed trypomastigote antigens.

Authors:  S P Nickell; M Keane; M So
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.